NuSil completes work on silicone facility

By Staff Reporter

- Last updated on GMT

Related tags Pharmacology

US firm NuSil Technology says new clean room manufacturing plant will help meet growing demand for silicone compounds for delivery systems.

Silicones, not to be confused with the element silicone, are polymer excipients with which active pharmaceutical ingredients (API) are combined, or compounded, enabling improved drug delivery.+

Nusil’s new 2,400 sqft facility, which is near the firm’s headquarters in California, will provide contract manufacturing and silicone compounding services for pharma and biotech industry clients.

Brian Reilly, NuSil’s product director for health care materials, explained that: “We’ve seen an increase in demand from manufacturers of controlled release and combination products to compound and deliver silicones that contain APIs.

As a direct result of that spike in interest, we felt it was time to make a capital investment in multiple facility expansions that would ensure all future compounding was done in a safe and controlled environment.”

Transdermal delivery

The completion of the new facility follows just days after NuSil expanded its range of drug delivery silicones (DDS) with two new transdermal adhesives.

The first new silicone, DDR-1370, is a pressure sensitive adhesive (PSA) designed to provide both “high cohesive strength and high release force,” which NuSil claim gives the material “favourable temporary adhesive properties.”

DDR-4355, in contrast, is a transparent, soft silicone gel that has a high-surface-tack, temporary silicone adhesive.

Speaking when the products launched on April 8, Reilly said that: “With a PSA and a tacky gel available to the transdermal drug delivery market, we are striving to offer two great options for temporary adhesives.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars